Regeneron Pharmaceuticals, Inc. (BIT:1REGN)
Italy · Delayed Price · Currency is EUR | Market Cap | 70.19B +36.9% |
| Revenue (ttm) | 13.60B +9.3% |
| Net Income | 3.79B -2.9% |
| EPS | 35.39 +1.9% |
| Shares Out | n/a |
| PE Ratio | 18.52 |
| Forward PE | 11.43 |
| Dividend | 3.18 (0.49%) |
| Ex-Dividend Date | Aug 17, 2026 |
| Volume | 1 |
| Open | 659.80 |
| Previous Close | 652.30 |
| Day's Range | 659.80 - 659.80 |
| 52-Week Range | 467.50 - 724.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron gets CHMP opinion recommending Libtayo alternative dosing schedule
Regeneron (REGN) announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the approval of an alternative dos...
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment
Regeneron assumed with Buy from Neutral at UBS
UBS upgraded Regeneron (REGN) to Buy from Neutral with a price target of $978, up from $660, after assuming coverage of the name. The shares at current levels are not…
Regeneron announces results from Phase 3 OPTIMA trial of Pasatru
Regeneron (REGN) Pharmaceuticals announced 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru in adults with fibrodysplasia ossificans progressiva. These longer-term findings for Pasatru...
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with ...
Regeneron price target raised to $908 from $891 at BofA
BofA raised the firm’s price target on Regeneron (REGN) to $908 from $891 and keeps a Buy rating on the shares after updating estimates ahead of the company’s Q3 report.
Regeneron price target raised to $810 from $737 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron (REGN) to $810 from $737 and keeps a Sector Perform rating on the shares as part of a…
Regeneron price target raised to $780 from $772 at Truist
Truist raised the firm’s price target on Regeneron (REGN) to $780 from $772 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Regeneron price target raised to $779 from $758 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $779 from $758 and keeps an Equal Weight rating on the shares. The firm adjusted its models for its…
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Regeneron price target raised to $950 from $900 at JPMorgan
JPMorgan raised the firm’s price target on Regeneron (REGN) to $950 from $900 and keeps an Overweight rating on the shares ahead of the Q3 report. The firm expects a…
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
Regeneron price target raised to $930 from $870 at Jefferies
Jefferies raised the firm’s price target on Regeneron (REGN) to $930 from $870 and keeps a Buy rating on the shares. The company’s expanded collaboration with Sanofi (SNY) on four…
Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $960 price target on Regeneron (REGN), saying the expanded agreement with Sanofi (SNY) enhances both companies’ ability to capitalize…
Regeneron says ubamatamab shows high rate of durable responses in initial study
Regeneron (REGN) Pharmaceuticals announced the first results for the investigational ubamatamab in patients with low-grade serous ovarian cancer. The data are from an ongoing Phase 1/2 trial in recurr...
Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss
Regeneron (REGN) Pharmaceuticals announced new results from the Phase 2 COURAGE trial evaluating trevogrumab for its potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induce...
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition...
Regeneron Pharmaceuticals Transcript: Collaboration
The expanded Sanofi alliance adds four long-acting antibodies, with equal sharing of development costs and global profits. The lead IL-13 program targets pivotal-study initiation in late 2027 or early 2028, while COPD data will inform a possible lunsekimig addition.
Regeneron Pharmaceuticals Slides: Collaboration
Regeneron Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Regeneron Pharmaceuticals Press release: Collaboration
Regeneron Pharmaceuticals issued a press release on October 1, 2026, disclosing material business information to investors.
Argus upgrades Regeneron on attractive entry point after selloff
Argus upgraded Regeneron (REGN) to Buy from Hold with an $850 price target The recent share pullback provides an attractive entry point, the analyst tells investors in a research note.
Regeneron upgraded to Buy from Hold at Argus
Argus analyst Jasper Hellweg upgraded Regeneron (REGN) to Buy from Hold with an $850 price target
Regeneron, Sanofi expand long-standing antibody collaboration
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-acting antibodies to the alliance that has...
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.